Harmony Biosciences Holdings Sees Stake Reduced by Nan Fung Group

Hedge fund cuts position in pharmaceutical company by over 90%

Mar. 14, 2026 at 9:33am

Got story updates? Submit your updates here. ›

Nan Fung Group Holdings Ltd. has reduced its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 92.7% during the third quarter, according to a recent SEC filing. The hedge fund now owns 27,049 shares of the company's stock, down from 341,616 shares previously.

Why it matters

Harmony Biosciences is a commercial-stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. The significant reduction in Nan Fung Group's position could signal a shift in investor sentiment or portfolio strategy for the hedge fund.

The details

According to the SEC filing, Nan Fung Group Holdings Ltd. sold 341,616 shares of Harmony Biosciences during the third quarter, leaving the firm with a remaining position of 27,049 shares. The hedge fund's holdings in Harmony Biosciences now make up about 1.2% of its total portfolio, down from a previous 5.9% stake.

  • Nan Fung Group reduced its Harmony Biosciences stake during the third quarter of 2026.

The players

Nan Fung Group Holdings Ltd.

A hedge fund that previously held a significant stake in Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc.

A commercial-stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases.

Got photos? Submit your photos here. ›

The takeaway

The substantial reduction in Nan Fung Group's position in Harmony Biosciences could indicate a shift in the hedge fund's investment strategy or outlook on the pharmaceutical company's prospects. However, without further details, it's difficult to determine the specific reasons behind the portfolio change.